Conjugation is the heart of Antibody-Drug Conjugate (ADC) technology. Where biology meets chemistry. At Aurigene, we offer state-of-the-art conjugation services that ensure precise, stable, and reproducible attachment of payloads to antibodies. Our deep understanding of bioconjugation science, coupled with advanced analytics, allows us to optimize every step, from site selection to linker-payload attachment. Enabling the creation of ADCs with optimal Drug-to-Antibody Ratios (DAR), stability, and therapeutic activity. Whether your goal is preclinical proof-of-concept or gram scale batches, we tailor conjugation strategies to your molecule’s biology, mechanism of action, and intended indication.
Thiol-Maleimide Conjugation
- Standard approach using reduced interchain cysteines
- Controlled DAR (typically 2, 4, or 8)
- Efficient and scalable
Ideal for fast turnaround and widely accepted in early-phase ADC development
Lysine Conjugation
- Non-specific conjugation to surface-exposed lysines
- Produces heterogeneous ADCs
Suitable for early-stage screening and rapid evaluation of new payloads or linkers
Enzymatic Conjugation
- Site-specific conjugation via transglutaminase, sortase, or glycoengineering
- High positional control and consistency
Best for developing next-gen, highly homogeneous ADCs
Branched and Dual Payload Conjugation
- Technologies to enable two different payloads on the same antibody
- Balanced DAR per payload
Designed to overcome tumor heterogeneity or resistance mechanisms
Site-Specific Technologies (Engineered Cysteines)
- Controlled site insertion for cleaner ADCs
Ensures uniform DAR and improved pharmacokinetics
Why choose Aurigene?
At Aurigene, conjugation isn’t just a chemical reaction, it’s a scientifically guided process. We bring over a decade of experience in designing and optimizing conjugation strategies across diverse payloads, linkers, and antibody formats, including bispecifics and Fab fragments. Our conjugation team works hand-in-hand with our analytical, purification, and in vitro biology teams to ensure each ADC meets stringent quality, reproducibility, and performance benchmarks.
We provide:
Expert design of DAR optimization and conjugation strategy
Multiple conjugation formats tailored to indication and payload class
Capability to support cleavable and non-cleavable linkers
Advanced purification to isolate mono-, di-, or specific DAR species
Fully integrated analytics including LC-MS, HIC, SEC, UV-Vis, and endotoxin testing
Seamless transition to in vitro assays, stability studies, and in vivo efficacy models
Whether you are screening novel linker-payloads or developing a clinical candidate, Aurigene ensures your conjugation step is robust, reproducible, and ready for scale-up.
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Methoxy Polyethylene Glycol (m-PEGs)
Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...
Read More
Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones
2020
A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...
Read More-
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation
2005
An improved and rapid synthesis of mefenamic acid based indole derivatives has been achieved via the ligand free Cu-catalyzed coupling-cyclization method under ultrasound irradiation. This simple, straightforward and inexpensive one-pot method involved the reaction of a terminal alkyne derived from mefenamic acid with 2- iodosulfanilides in the presence of CuI ...
Read More -
Formal synthesis of Cladospolide C & epi-Cladospolide C using R- (þ)-g-valerolactone as a chiral synthon
2005
The formal synthesis of Cladospolide-C and its analog is achieved by using enantiopure (R)-g evalerolactone 10. The significant points of this synthesis are the stereoselective dihydroxylation of a, bunsaturated ester 16 using Sharpless protocol, Wittig olefination of g evalerolactol 6 with triphenylphosphonium iodide salt 7, one pot selective oxidation ...
Read More -
Amberlite-15 promoted an unprecedented aza Michael rearrangement for one pot synthesis of dihydroquinazolinone compounds
2005
A new one pot multicomponent annulation strategy for the synthesis of various dihydroquinazolinone compounds has been developed using Amberlite-15 as a catalyst, giving good to moderate yields. In this reaction the substrate scope for amines and aldehydes was also investigated. The reaction has been checked on a large scale ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market